Lucia Parlati
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Lucia Parlati has a total of 212 co-authors. Here are the top co-authors by number of shared publications:
Philippe Sogni
4 shared publications- Vincent Mallet
Université Paris Cité, Paris, France
4 shared publications Samir Bouam
3 shared publicationsStanislas Pol
3 shared publications- Stanislas Pol
Groupe Hospitalier Cochin Port Royal, DMU Cancérologie et Spécialités Médico-Chirurgicales, Service d'Hépatologie, AP-HP Centre, Université Paris Cité, 75014 Paris, France
3 shared publications Benoit Terris
Université de Paris Service d'anatomopathologie, Assistance Publique des hôpitaux de Paris, Hôpital Cochin Paris France
2 shared publications
Latest Publications
- Open Access
Gut microbiome profiles associated with simple liver steatosis in MASLD
Background Alterations in the gut microbiota have been linked to metabolic dysfunction-associated steatotic liver disease (MASLD). However, most studies have focused on advanced disease stages with limited consideration of the impact of medications such as proton pump inhibitors and metformin. Objective To characterise the gut microbiota signatures in individuals with simple steatosis, free from such confounders, across three European cohorts spanning a broad range of body mass index. Design Faecal samples from 134 participants were analysed by whole-genome metagenomic sequencing. Participants included biopsy-confirmed steatosis cases and controls from Austria (18 vs 18) and Italy (20 vs 12), and ultrasound-diagnosed steatosis from Sweden (33 vs 33). Results Simple steatosis was associated with a gut microbiota profile characterised by reduced microbial gene richness and decreased abundance of butyrate-producing species. These alterations appeared in the absence of histological steatohepatitis or significant fibrosis, indicating that microbial shifts occur before advanced disease and are not simply a consequence of disease progression. Across all cohorts, enrichment of oral-origin and small intestinal-origin bacteria, including opportunistic pathogens such as Fusobacterium nucleatum and Klebsiella oxytoca, was consistently observed in steatosis. Furthermore, gut microbiota profiles associated with steatosis exhibited increased genetic potential for lipopolysaccharide biosynthesis, suggesting an enhanced capacity for systemic inflammatory signalling. Conclusion Gut microbiota alterations occur early in MASLD before advanced inflammatory or fibrotic disease. The consistent enrichment of oral-origin and pro-inflammatory taxa across cohorts suggests that both oral-gut and gut-liver axes may contribute to steatosis pathogenesis, independent of common pharmacological confounders.
Open AccessGut microbiome profiles associated with simple liver steatosis in MASLD
Background Alterations in the gut microbiota have been linked to metabolic dysfunction-associated steatotic liver disease (MASLD). However, most studies have focused on advanced disease stages with limited consideration of the impact of medications such as proton pump inhibitors and metformin. Objective To characterise the gut microbiota signatures in individuals with simple steatosis, free from such confounders, across three European cohorts spanning a broad range of body mass index. Design Faecal samples from 134 participants were analysed by whole-genome metagenomic sequencing. Participants included biopsy-confirmed steatosis cases and controls from Austria (18 vs 18) and Italy (20 vs 12), and ultrasound-diagnosed steatosis from Sweden (33 vs 33). Results Simple steatosis was associated with a gut microbiota profile characterised by reduced microbial gene richness and decreased abundance of butyrate-producing species. These alterations appeared in the absence of histological steatohepatitis or significant fibrosis, indicating that microbial shifts occur before advanced disease and are not simply a consequence of disease progression. Across all cohorts, enrichment of oral-origin and small intestinal-origin bacteria, including opportunistic pathogens such as Fusobacterium nucleatum and Klebsiella oxytoca, was consistently observed in steatosis. Furthermore, gut microbiota profiles associated with steatosis exhibited increased genetic potential for lipopolysaccharide biosynthesis, suggesting an enhanced capacity for systemic inflammatory signalling. Conclusion Gut microbiota alterations occur early in MASLD before advanced inflammatory or fibrotic disease. The consistent enrichment of oral-origin and pro-inflammatory taxa across cohorts suggests that both oral-gut and gut-liver axes may contribute to steatosis pathogenesis, independent of common pharmacological confounders.
- 18 August 2026
- Published by Wiley in Liver International
- Vol. 46 (9) , e70806
Hepatology: Emerging Paradigms in MASLD, Viral Hepatitis, Cholestatic Liver Disease, Portal Hypertension and Hepatocellular Carcinoma
The Paris International Liver Meeting (January 19–21, 2026) brought together leading hepatology experts to discuss transformative advances in chronic liver disease management. The meeting highlighted pivotal developments reflecting the field's evolution from disease characterisation toward precision, mechanism‐based therapeutics. Metabolic dysfunction‐associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‐associated steatohepatitis (MASH), were highlighted, marking the transition to an era of approved disease‐modifying therapies. Resmetirom and semaglutide are now approved for MASH with F2–F3 fibrosis, with a robust pipeline generating anti‐fibrotic signals through FGF21 analogs, pan‐peroxisome proliferator‐activated receptor (PPAR) agonists, and incretin‐based dual and triple agonists. Non‐invasive tests have evolved beyond their original diagnostic role to enable prognostic stratification, screening of at‐risk populations, treatment selection, and monitoring of therapeutic response. This evolution is not limited to MASLD, but extends to other chronic liver diseases, including primary biliary cholangitis (PBC) and portal hypertension, as highlighted by the recommendations of the Baveno Consensus Workshops. Hepatitis B and D are moving toward functional cure strategies, with simplified HBV treatment algorithms based on fibrosis and viral load, supported by biomarkers for risk stratification and safe treatment discontinuation. In parallel, HDV management is transitioning from a severe disease to one with emerging suppressive and potential curative l through bulevirtide and novel HBsAg‐targeting and RNA‐silencing therapies, respectively. Management of PBC has advanced with novel PPAR agonists that improve cholestatic biochemistry and pruritus, supported by individualised risk stratification. However, significant treatment gaps persist, with fewer than half of eligible PBC patients receiving second‐line therapy, and fatigue remains a major unmet clinical need. Furthermore, effective pharmacotherapies for primary sclerosing cholangitis (PSC) remain a major challenge, and no approved disease‐modifying treatments are currently available. Finally, for patients with hepatocellular carcinoma (HCC), immunotherapy combinations can achieve unprecedented long‐term survival in selected populations of patients. Collectively, these advances define a new era of hepatology centered on precision medicine, earlier intervention, and mechanism‐driven therapeutic strategies.
- 18 August 2026
- Published by Wiley in Liver International
- Vol. 46 (9) , e70806
Hepatology: Emerging Paradigms in MASLD, Viral Hepatitis, Cholestatic Liver Disease, Portal Hypertension and Hepatocellular Carcinoma
The Paris International Liver Meeting (January 19–21, 2026) brought together leading hepatology experts to discuss transformative advances in chronic liver disease management. The meeting highlighted pivotal developments reflecting the field's evolution from disease characterisation toward precision, mechanism‐based therapeutics. Metabolic dysfunction‐associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‐associated steatohepatitis (MASH), were highlighted, marking the transition to an era of approved disease‐modifying therapies. Resmetirom and semaglutide are now approved for MASH with F2–F3 fibrosis, with a robust pipeline generating anti‐fibrotic signals through FGF21 analogs, pan‐peroxisome proliferator‐activated receptor (PPAR) agonists, and incretin‐based dual and triple agonists. Non‐invasive tests have evolved beyond their original diagnostic role to enable prognostic stratification, screening of at‐risk populations, treatment selection, and monitoring of therapeutic response. This evolution is not limited to MASLD, but extends to other chronic liver diseases, including primary biliary cholangitis (PBC) and portal hypertension, as highlighted by the recommendations of the Baveno Consensus Workshops. Hepatitis B and D are moving toward functional cure strategies, with simplified HBV treatment algorithms based on fibrosis and viral load, supported by biomarkers for risk stratification and safe treatment discontinuation. In parallel, HDV management is transitioning from a severe disease to one with emerging suppressive and potential curative l through bulevirtide and novel HBsAg‐targeting and RNA‐silencing therapies, respectively. Management of PBC has advanced with novel PPAR agonists that improve cholestatic biochemistry and pruritus, supported by individualised risk stratification. However, significant treatment gaps persist, with fewer than half of eligible PBC patients receiving second‐line therapy, and fatigue remains a major unmet clinical need. Furthermore, effective pharmacotherapies for primary sclerosing cholangitis (PSC) remain a major challenge, and no approved disease‐modifying treatments are currently available. Finally, for patients with hepatocellular carcinoma (HCC), immunotherapy combinations can achieve unprecedented long‐term survival in selected populations of patients. Collectively, these advances define a new era of hepatology centered on precision medicine, earlier intervention, and mechanism‐driven therapeutic strategies.
- 7 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Rôle de la O-GlcNAc transférase (OGT) dans la physiopathologie hépatique
La O-GlcNAcylation est une modification post-traductionnelle dynamique et réversible contrôlée par l'activité de deux enzymes, la O-GlcNAc transférase (OGT) et la O-GlcNAcase (OGA). Ces deux enzymes interviennent dans le cycle dynamique de la O-GlcNAcylation sur une grande variété de protéines cytosoliques, nucléaires et mitochondriales d'une manière sensible aux nutriments et au stress (Yang et Qian, 2017). En conséquence, il a été proposé que la O-GlcNAcylation fonctionne comme un capteur de nutriments et de stress régulant les processus cellulaires allant de la transcription et de la traduction à la transduction du signal et au métabolisme. La perturbation de l'homéostasie de l'O-GlcNAcylation a été impliquée dans la pathogenèse de plusieurs maladies humaines, notamment le cancer, le diabète et la neurodégénérescence (Nie et Yi, 2019). Une étude récente a suggéré que l'OGT agit comme un suppresseur de la nécroptose des hépatocytes (une forme spécifique de nécrose régulée) et que la suppression de l'OGT dans le foie des souris déclenche une fibrose hépatique (Zhang et al., 2019). Dans ce contexte, nous avons cherché à déterminer les conséquences d'une délétion ciblée de l'enzyme OGT dans les hépatocytes in vivo et à explorer l'effet d'un changement alimentaire sur le phénotype hépatique. En utilisant des souris présentant un déficit ciblé en OGT dans les hépatocytes (OGTLKO), notre étude révèle que l'OGT est essentiel à l'homéostasie du foie. En utilisant des souris présentant un déficit ciblé en OGT dans les hépatocytes (OGTLKO), notre étude révèle que l'OGT est essentiel à l'homéostasie du foie. Nous avons démontré que l'absence d'OGT est associée à un stress oxydatif, à une inflammation et à une fibrose modérée à 2 semaines, entraînant une fibrose hépatique avancée et l'apparition de nodules de régénération à 8 semaines. Étant donné que l'apport en glucides induit un stress oxydatif (Du et al., 2010 ; Mohanty et al., 2000 ; de Carvalho Vidigal et al., 2012 ; Dickinson et al., 2008), nous avons émis l'hypothèse que le stress oxydatif élevé observé dans le foie pendant 4 semaines était lié à l'augmentation des sucres dans le régime au sevrage. Pour tester cette hypothèse, les souris OGTLWT et OGTLKO ont été sevrés avec un régime pauvre en glucides compensé par une augmentation des lipides (LFHC: 21 % de glucides, 60 % de lipides, 19 % de protéines), ou un régime cétogène (KD: 1 % de glucides, 94% de lipides, 5 % de protéines) ou un régime standard (SD: 69 % de glucides, 4 % de lipides, 26% de protéines). Alors que les régimes LCHF et KD prévenaient le stress oxydatif hépatique chez les souris OGTLKO, seul le KD permettait la réversion complète du phénotype OGTLKO (y compris les lésions hépatiques et la fibrose), ce qui suggère que la réduction de l'apport en glucides au sevrage prévient l'effet délétère de l'absence de l'OGT dans le foie. Compte tenu du phénotype hépatique observé chez les souris OGTLKO nous avons voulu caractériser un modèle original avec une délétion inductible de l'OGT hépatocytaire (OGTINDLKO) et nous avons démontré que le rôle de l'OGT dans le maintien de l'homéostasie hépatique est indépendant de l'âge de la souris. Enfin, vu rôle de l'OGT dans les processus métaboliques de lipogenèse hépatique, nous avons exploré le niveau de l'OGT et de la O-GlcNAcylation dans une population de patients avec une NAFLD et ayant subi une chirurgie bariatrique pour une obesité morbide (Cohorte Abos-CHU de Lille).
- 7 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Rôle de la O-GlcNAc transférase (OGT) dans la physiopathologie hépatique
La O-GlcNAcylation est une modification post-traductionnelle dynamique et réversible contrôlée par l'activité de deux enzymes, la O-GlcNAc transférase (OGT) et la O-GlcNAcase (OGA). Ces deux enzymes interviennent dans le cycle dynamique de la O-GlcNAcylation sur une grande variété de protéines cytosoliques, nucléaires et mitochondriales d'une manière sensible aux nutriments et au stress (Yang et Qian, 2017). En conséquence, il a été proposé que la O-GlcNAcylation fonctionne comme un capteur de nutriments et de stress régulant les processus cellulaires allant de la transcription et de la traduction à la transduction du signal et au métabolisme. La perturbation de l'homéostasie de l'O-GlcNAcylation a été impliquée dans la pathogenèse de plusieurs maladies humaines, notamment le cancer, le diabète et la neurodégénérescence (Nie et Yi, 2019). Une étude récente a suggéré que l'OGT agit comme un suppresseur de la nécroptose des hépatocytes (une forme spécifique de nécrose régulée) et que la suppression de l'OGT dans le foie des souris déclenche une fibrose hépatique (Zhang et al., 2019). Dans ce contexte, nous avons cherché à déterminer les conséquences d'une délétion ciblée de l'enzyme OGT dans les hépatocytes in vivo et à explorer l'effet d'un changement alimentaire sur le phénotype hépatique. En utilisant des souris présentant un déficit ciblé en OGT dans les hépatocytes (OGTLKO), notre étude révèle que l'OGT est essentiel à l'homéostasie du foie. En utilisant des souris présentant un déficit ciblé en OGT dans les hépatocytes (OGTLKO), notre étude révèle que l'OGT est essentiel à l'homéostasie du foie. Nous avons démontré que l'absence d'OGT est associée à un stress oxydatif, à une inflammation et à une fibrose modérée à 2 semaines, entraînant une fibrose hépatique avancée et l'apparition de nodules de régénération à 8 semaines. Étant donné que l'apport en glucides induit un stress oxydatif (Du et al., 2010 ; Mohanty et al., 2000 ; de Carvalho Vidigal et al., 2012 ; Dickinson et al., 2008), nous avons émis l'hypothèse que le stress oxydatif élevé observé dans le foie pendant 4 semaines était lié à l'augmentation des sucres dans le régime au sevrage. Pour tester cette hypothèse, les souris OGTLWT et OGTLKO ont été sevrés avec un régime pauvre en glucides compensé par une augmentation des lipides (LFHC: 21 % de glucides, 60 % de lipides, 19 % de protéines), ou un régime cétogène (KD: 1 % de glucides, 94% de lipides, 5 % de protéines) ou un régime standard (SD: 69 % de glucides, 4 % de lipides, 26% de protéines). Alors que les régimes LCHF et KD prévenaient le stress oxydatif hépatique chez les souris OGTLKO, seul le KD permettait la réversion complète du phénotype OGTLKO (y compris les lésions hépatiques et la fibrose), ce qui suggère que la réduction de l'apport en glucides au sevrage prévient l'effet délétère de l'absence de l'OGT dans le foie. Compte tenu du phénotype hépatique observé chez les souris OGTLKO nous avons voulu caractériser un modèle original avec une délétion inductible de l'OGT hépatocytaire (OGTINDLKO) et nous avons démontré que le rôle de l'OGT dans le maintien de l'homéostasie hépatique est indépendant de l'âge de la souris. Enfin, vu rôle de l'OGT dans les processus métaboliques de lipogenèse hépatique, nous avons exploré le niveau de l'OGT et de la O-GlcNAcylation dans une population de patients avec une NAFLD et ayant subi une chirurgie bariatrique pour une obesité morbide (Cohorte Abos-CHU de Lille).
- Open Access
- 3 February 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (4) , 101740
Comparative evaluation of regression and machine-learning models for hepatocellular carcinoma risk stratification across diverse aetiologies
- 3 February 2026
- Published by Elsevier in JHEP Reports
- Vol. 8 (4) , 101740
Open AccessComparative evaluation of regression and machine-learning models for hepatocellular carcinoma risk stratification across diverse aetiologies
- Open Access
- 5 July 2025
- Published by Elsevier in JHEP Reports
- Vol. 7 (10)
Cystic fibrosis liver disease progression in the era of elexacaftor–tezacaftor–ivacaftor
- 5 July 2025
- Published by Elsevier in JHEP Reports
- Vol. 7 (10)
Open AccessCystic fibrosis liver disease progression in the era of elexacaftor–tezacaftor–ivacaftor
- Open Access
- 9 April 2025
- Published by Elsevier in Diagnostic and Interventional Imaging
- Vol. 106 (7-8) , 272-279
SIAD (Societé d'Imagerie Abdominale et Digestive) and AFEF (Association Française pour l'Etude du Foie) best practice position paper on the implementation of ultrasound elastography in clinical practice
- 9 April 2025
- Published by Elsevier in Diagnostic and Interventional Imaging
- Vol. 106 (7-8) , 272-279
Open AccessSIAD (Societé d'Imagerie Abdominale et Digestive) and AFEF (Association Française pour l'Etude du Foie) best practice position paper on the implementation of ultrasound elastography in clinical practice
- Open Access
- 15 March 2025
- Published by Wiley in Liver International
- Vol. 45 (4) , e70065
Behaviour‐Based Predictive Scores of Hepatocellular Carcinoma in People With Chronic Hepatitis B ( ANRS CO22 HEPATHER )
Background and Aims: Early assessment of hepatocellular carcinoma (HCC) risk could improve long‐term outcomes in people with chronic hepatitis B virus (HBV) infection. Some existing HCC predictive scores are not easily implementable. We developed easy‐to‐use HCC predictive scores based on behavioural and routine bio‐clinical data in people with chronic HBV infection. Methods: Eight‐year follow‐up data was analysed from people with chronic HBV infection enrolled in the French ANRS CO22 HEPATHER cohort. Patients were randomly split into two samples (training/testing). A multivariable Cox model for time to HCC was estimated on the training sample. The HCC predictive score was computed by summing the points assigned to model predictors, normalising their coefficients over a 10‐year age increment, and rounding to the nearest integer. The Youden index identified the score's optimal risk threshold. Comparisons with existing predictive scores were performed on the testing sample. Results: In the study population ( N = 4370; 63% of men; 65% of < 50 years old), 56 HCC cases occurred during 25,900 follow‐up person‐years. Two HCC predictive scores were defined: SADAPTT (daily soft drink consumption, age, hepatitis Delta infection, unhealthy alcohol use, platelet count, heavy tobacco smoking, and HBV treatment) and ADAPTT (the same predictors except for daily soft drink consumption), with ranges 0–13 and 0–14, respectively, and values ≥ 3 indicating a high HCC risk. Their performances were similar to existing scores. Conclusions: We developed two effective behaviour‐based HCC predictive scores, implementable in many settings, including primary care and decentralised areas. Further studies are needed to validate these scores in other datasets.
- 15 March 2025
- Published by Wiley in Liver International
- Vol. 45 (4) , e70065
Open AccessBehaviour‐Based Predictive Scores of Hepatocellular Carcinoma in People With Chronic Hepatitis B ( ANRS CO22 HEPATHER )
Background and Aims: Early assessment of hepatocellular carcinoma (HCC) risk could improve long‐term outcomes in people with chronic hepatitis B virus (HBV) infection. Some existing HCC predictive scores are not easily implementable. We developed easy‐to‐use HCC predictive scores based on behavioural and routine bio‐clinical data in people with chronic HBV infection. Methods: Eight‐year follow‐up data was analysed from people with chronic HBV infection enrolled in the French ANRS CO22 HEPATHER cohort. Patients were randomly split into two samples (training/testing). A multivariable Cox model for time to HCC was estimated on the training sample. The HCC predictive score was computed by summing the points assigned to model predictors, normalising their coefficients over a 10‐year age increment, and rounding to the nearest integer. The Youden index identified the score's optimal risk threshold. Comparisons with existing predictive scores were performed on the testing sample. Results: In the study population ( N = 4370; 63% of men; 65% of < 50 years old), 56 HCC cases occurred during 25,900 follow‐up person‐years. Two HCC predictive scores were defined: SADAPTT (daily soft drink consumption, age, hepatitis Delta infection, unhealthy alcohol use, platelet count, heavy tobacco smoking, and HBV treatment) and ADAPTT (the same predictors except for daily soft drink consumption), with ranges 0–13 and 0–14, respectively, and values ≥ 3 indicating a high HCC risk. Their performances were similar to existing scores. Conclusions: We developed two effective behaviour‐based HCC predictive scores, implementable in many settings, including primary care and decentralised areas. Further studies are needed to validate these scores in other datasets.
- 10 January 2025
- Published by Wiley in Liver International
- Vol. 45 (2) , e16232
Liver Disease Complicating Familial Mediterranean Fever: A Study on 66 Patients Out of 533 Adult From the JIR Cohort
Background: Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disease, associated with MEFV mutations. FMF patients can experience liver involvement, potentially leading to cirrhosis.Objectives: This study aimed to evaluate liver involvement in FMF patients at a French tertiary centre for adult FMF.Methods: We conducted an observational study with FMF patients displaying 2 pathogenic MEFV mutations at the National Reference Center for Autoinflammatory Diseases and Inflammatory Amyloidosis (CEREMAIA) in Paris and included in the JIR cohort. MEFV heterozygous patients and those with other liver disease causes were excluded.Results: Among 533 FMF patients 12.4% had chronic liver abnormalities, with 30% who developed cirrhosis 54 years [36–57] in median after disease onset. Forty‐seven per cent were colchicine resistant, and 41% received interleukin‐1 inhibitors. Cirrhotic patients experienced delayed hepatopathy diagnosis, prolonged FMF diagnosis delay and late‐onset treatment initiation compared to those with only liver function test abnormalities. Colchicine resistance and interleukin‐1 inhibitor use were more common in cirrhotic patients. Body mass index and AA amyloidosis rates did not differ significantly between groups. Twenty‐one patients had undergone liver biopsies including 14 cirrhotic patients revealing steatohepatitis in 12 cases and probable steatohepatitis in 4. Other lesions, like iron overload and sinusoidal dilatation, were sporadically observed.Conclusion: FMF patients are at risk of chronic liver disease. Regular liver function monitoring is crucial, particularly in case of persistent inflammation, due to the risk of progression to cirrhosis and its associated morbidity and mortality.
- 10 January 2025
- Published by Wiley in Liver International
- Vol. 45 (2) , e16232
Liver Disease Complicating Familial Mediterranean Fever: A Study on 66 Patients Out of 533 Adult From the JIR Cohort
Background: Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disease, associated with MEFV mutations. FMF patients can experience liver involvement, potentially leading to cirrhosis.Objectives: This study aimed to evaluate liver involvement in FMF patients at a French tertiary centre for adult FMF.Methods: We conducted an observational study with FMF patients displaying 2 pathogenic MEFV mutations at the National Reference Center for Autoinflammatory Diseases and Inflammatory Amyloidosis (CEREMAIA) in Paris and included in the JIR cohort. MEFV heterozygous patients and those with other liver disease causes were excluded.Results: Among 533 FMF patients 12.4% had chronic liver abnormalities, with 30% who developed cirrhosis 54 years [36–57] in median after disease onset. Forty‐seven per cent were colchicine resistant, and 41% received interleukin‐1 inhibitors. Cirrhotic patients experienced delayed hepatopathy diagnosis, prolonged FMF diagnosis delay and late‐onset treatment initiation compared to those with only liver function test abnormalities. Colchicine resistance and interleukin‐1 inhibitor use were more common in cirrhotic patients. Body mass index and AA amyloidosis rates did not differ significantly between groups. Twenty‐one patients had undergone liver biopsies including 14 cirrhotic patients revealing steatohepatitis in 12 cases and probable steatohepatitis in 4. Other lesions, like iron overload and sinusoidal dilatation, were sporadically observed.Conclusion: FMF patients are at risk of chronic liver disease. Regular liver function monitoring is crucial, particularly in case of persistent inflammation, due to the risk of progression to cirrhosis and its associated morbidity and mortality.
- 30 August 2024
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 23 (5) , 808-815.e5
Alcohol Rehabilitation Within 3 Months After Alcohol Hepatitis and Survival: A National Analysis
- 30 August 2024
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 23 (5) , 808-815.e5
Alcohol Rehabilitation Within 3 Months After Alcohol Hepatitis and Survival: A National Analysis